[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Craigavon Area Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100585222",false,"NCT06899555","REgistry of Paclitaxel Coated Drug Eluting Balloon in All Comers PaTients","REgistry of Paclitaxel Coated Drug Eluting Balloon in All Comers PaTients (REPEAT Registry)","REPEAT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with symptomatic coronary artery disease (including those with acute coronary syndromes or Chronic Coronary Syndromes) with either symptoms and\u002For ischaemia.\n* The patient must be able to understand and provide informed consent and comply with all study procedures.\n\nCoronary angiographic inclusion criteria:\n\n* ≥70% target lesion stenosis in LAD, LCX or RCA (or branches) which after successful pre-dilatation\\* has a residual stenosis ≤ 30% and no dissection of Type C or greater than (NHLBI guidelines)\n\n  \\*pre-dilation permitted with SC or NC balloon catheter, cutting\u002Fscoring balloon, rotational\u002Forbital atherectomy, or laser\n* Target vessel reference diameter between 2.0 and 4.5 mm.\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction (LVEF) ≤ 30%\n* Acute ST elevation MI (STEMI)\n* Cardiogenic shock within 2 days prior to the index PCI.\n* Known contraindication or hypersensitivity to paclitaxel, and\u002For to any anti-thrombotic and anti-platelet class of drugs\n* Allergy to imaging contrast media which cannot be adequately pre-medicated.\n* Patient undergoing planned surgery within 3 months with the necessity to stop dual antiplatelet therapy (DAPT).\n* Patient is pregnant or breast feeding.\n* Patient has received a heart transplant.\n* Patient is unwilling or unable to give follow-up until study completion.\n* Patient is currently participating in another trial.\n* Life expectancy \\\u003C1 year.\n\nAngiographic exclusion criteria:\n\n* Target lesion in the left main coronary artery.\n* Flow limiting target vessel thrombus\n* Vessel dissection requiring bailout stenting.","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","1 Year","OBSERVATIONAL","A post marketing, observational , multi centre, prospective registry to assess safety and performance of the Drug Eluting Balloon in patients undergoing percutaneous coronary intervention.\n\nRational : Although DEBs are generally considered safe, there remain many unanswered questions about DEB technology in a real-world population and only limited trial data from geographically or clinically diverse patient subgroups. To address some of the clinical and translational gaps in knowledge we thus plan a clinical registry to assess safety and performance of a novel design of a drug eluting\n\nA real-world, all-comers coronary artery disease (CAD) population undergoing percutaneous coronary intervention (PCI) and suitable for treatment with a Paclitaxel Coated Coronary Balloon Dilatation Catheter.\n\nStudy Population - 500 Patients",[25],"CAD - Coronary Artery Disease","NOT_YET_RECRUITING","2025-03-21",{"date":29,"type":30},"2025-03-28","ACTUAL",{"date":32,"type":20},"2025-05",{"date":34,"type":20},"2027-05",{"name":36,"class":37},"Craigavon Area Hospital","OTHER",""]